Startups
2021
ATG THERAPEUTICS SL We develop novel classes of drugs and biomarkers to prevent cancer therapeutic resistance
Advance our portfolio of therapies to clinical trials and improve the lives of those affected by cancer therapeutic resistance
Advance our portfolio of therapies to clinical trials and improve the lives of those affected by cancer therapeutic resistance
Address
Avinguda de la Granvia de l’Hospitalet 199, 08908 L'Hospitalet de Llobregat, Spain
Finance Data
CERCA ownership
L'Hospitalet de Llobregat, Spain
2004
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)
CERCA Center Contact
LT
Laia TravesetResponsable innovació
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)Other Catalan Public owners
Logo
Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
The Angiotheragnostics (AtG) team has identified and validated a new therapeutic target to prevent anti-angiogenics resistance, as well as a plasma biomarker that selects patients that will benefit from the treatment. They are now in the early stages of developing this drug and biomarker kit, the first of its kind to target anti-angiogenics resistance.
AtG has identified two families of small molecules that inhibit this target protein, reducing its proliferation in cancer cell lines and impairing tumor growth after anti-angiogenic therapy fails.
AtG has identified two families of small molecules that inhibit this target protein, reducing its proliferation in cancer cell lines and impairing tumor growth after anti-angiogenic therapy fails.
Product description
Our findings:
Novel mechanism of action - Innovative anti-cancer therapeutic target
Drug candidate - New small molecule candidates
New biomarker - Patient selection technology
Technology
Angiotheragnostics’ technology is based on our unique ability to design and develop strategies that selectively target and eliminate cancer cells resistant to anti-angiogenic therapy
How it works
Determine plasma levels of RF-1 in metastatic kidney patients
Selection of patients with higher RF-1 levels
Treatment with RF-1 inhibitor
Novel mechanism of action - Innovative anti-cancer therapeutic target
Drug candidate - New small molecule candidates
New biomarker - Patient selection technology
Technology
Angiotheragnostics’ technology is based on our unique ability to design and develop strategies that selectively target and eliminate cancer cells resistant to anti-angiogenic therapy
How it works
Determine plasma levels of RF-1 in metastatic kidney patients
Selection of patients with higher RF-1 levels
Treatment with RF-1 inhibitor